targeted-therapies
(3)
Character Biosciences
Character Biosciences is a precision medicine company developing targeted therapies for progressive polygenic diseases, starting in ophthalmology with age-related macular degeneration (AMD). By pairing human genetics with longitudinal clinical and retinal imaging data from thousands of consented patients - and layering AI-enabled biomarker analysis on top - Character reclassifies broad diagnoses into genetically defined subtypes so it can design drugs that target the root drivers of disease progression. Its lead programs, CTX114 (a complement inhibitor for geographic atrophy) and CTX203 (a lipid regulator to prevent progression to advanced AMD), are advancing toward the clinic on the strength of a Series B that grew past $110 million.
Sporos Bioventures
Sporos Bioventures is a Houston-based private biotechnology company that builds and operates a portfolio of oncology and immune-disease startups under one roof. Rather than launching companies one at a time, Sporos pools capital, drug-discovery infrastructure, and operational expertise across multiple programs - including Tvardi Therapeutics, Asylia Therapeutics, Nirogy Therapeutics, Stellanova Therapeutics, and its internal Sporos BioDiscovery group - to move targeted cancer therapies from idea to early clinical trials faster and with less duplicated risk.
Synnovation Therapeutics
Synnovation Therapeutics is a Wilmington, Delaware precision medicine company building small-molecule cancer drugs aimed at validated oncology targets where greater potency and selectivity could beat the current standard of care. Founded in 2024 by a team of former Incyte medicinal chemistry leaders, it launched with a $102 million Series A led by Third Rock Ventures. Its lead programs are SNV1521, a CNS-penetrant, highly selective PARP1 inhibitor, and SNV4818, a mutant-selective PI3K-alpha inhibitor whose subsidiary Pikavation Therapeutics was acquired by Novartis in March 2026 for $2 billion upfront.